Urine catecholamines in paediatrics

Archives of Disease in Childhood: Education and Practice Edition

Volumn 96, Issue 3, 2011, Pages 107-111

  Erdelyi, Daniel J ^a   Elliott, Martin ^a   Phillips, Bob ^a  

^a Leeds General Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ADRENALIN; AMINOPHYLLINE; CAFFEINE; CATECHOLAMINE; DOPAMINE; ERYTHROMYCIN; HOMOVANILLIC ACID; IMIPRAMINE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; SALICYLIC ACID; TYROSINE 3 MONOOXYGENASE; VANILMANDELIC ACID;

ADRENAL MEDULLA; ADRENALIN URINE LEVEL; CANCER SCREENING; CANCER STAGING; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE METABOLISM; CATECHOLAMINE SYNTHESIS; CATECHOLAMINE URINE LEVEL; CHILDHOOD CANCER; CHOLINERGIC ACTIVITY; CIRCADIAN RHYTHM; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; MASS SPECTROMETRY; NEUROBLASTOMA; NORADRENALIN URINE LEVEL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY; URINALYSIS;

ADRENAL GLAND NEOPLASMS; CATECHOLAMINES; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; NEUROBLASTOMA; PHEOCHROMOCYTOMA; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING;

EID: 79956318376     PISSN: 17430585     EISSN: 17430593     Source Type: Journal    
DOI: 10.1136/adc.2010.207126     Document Type: Review

References (34)

1. Tsunoda M. Recent advances in methods for the analysis of catecholamines and their metabolites. Anal Bioanal Chem 2006;386:506-14. (Pubitemid 44461095)
2. Ganong WF. The adrenal medulla and adrenal cortex. In: Ganong WF, ed. Review of Medical Physiology. 2004:270-92.
3. Willemsen JJ, Ross HA, Lenders JW, et al. Stability of urinary fractionated metanephrines and catecholamines during collection, shipment, and storage of samples. Clin Chem 2007;53:268-72. (Pubitemid 46338271)
4. LaBrosse EH, Com-Nougué C, Zucker JM, et al. Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy- 4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors. Cancer Res 1980;40:1995-2001. (Pubitemid 10116127)
5. Monsaingeon M, Perel Y, Simonnet G, et al. Comparative values of catecholamines and metabolites for the diagnosis of neuroblastoma. Eur J Pediatr 2003;162:397-402. (Pubitemid 36693740)
6. Candito M, Thyss A, Albertini M, et al. Methylated catecholamine metabolites for diagnosis of neuroblastoma. Med Pediatr Oncol 1992;20:215-20.
7. Bell S, Parker L, Craft AW, et al. False positive results in a neuroblastoma screening programme. Med Pediatr Oncol 1994;22:181-6. (Pubitemid 24054764)
8. Berthold F, Hunneman DH, Harms D, et al. Serum vanillylmandelic acid/homovanillic acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma. Eur J Cancer 1992;28A:1950-4.
9. Craft AW, Parker L, Dale G, et al. A pilot study of screening for neuroblastoma in the north of England. Am J Pediatr Hematol Oncol 1992;14:337-41.
10. Graham-Pole J, Salmi T, Anton AH, et al. Tumor and urine catecholamines (CATs) in neurogenic tumors. Correlations with other prognostic factors and survival. Cancer 1983;51:834-9.
11. Hiyama E, Iehara T, Sugimoto T, et al. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study. Lancet 2008;371:1173-80. (Pubitemid 351458522)
12. Kellie SJ, Clague AE, McGeary HM, et al. The value of catecholamine metabolite determination on untimed urine collections in the diagnosis of neural crest tumours in children. Aust Paediatr J 1986;22:313-15. (Pubitemid 17018830)
13. Strenger V, Kerbl R, Dornbusch HJ, et al. Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients. Pediatr Blood Cancer 2007;48:504-9. (Pubitemid 46496343)
14. Mahoney NR, Liu GT, Menacker SJ, et al. Pediatric horner syndrome: etiologies and roles of imaging and urine studies to detect neuroblastoma and other responsible mass lesions. Am J Ophthalmol 2006;142:651-9.
15. Zambrano E, Reyes-Múgica M. Hormonal activity may predict aggressive behavior in neuroblastoma. Pediatr Dev Pathol 2002;5:190-9. (Pubitemid 34475453)
16. Sullivan JM, Solomon HS. The diagnosis of pheochromocytoma. Overnight excretion of catecholamine metabolites. JAMA 1975;231:618-19.
17. Gregianin LJ, McGill AC, Pinheiro CM, et al. Vanilmandelic acid and homovanillic acid levels in patients with neural crest tumor: 24-hour urine collection versus random sample. Pediatr Hematol Oncol 1997;14:259-65.
18. Tuchman M, Ramnaraine ML, Woods WG, et al. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma. Pediatrics 1987;79:203-5. (Pubitemid 17011066)
19. Ladenstein R, Valteau-Couanet D, Brock P, et al. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol 2010;28:3516-24.
20. Kushner BH, Kramer K, Modak S, et al. Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol 2009;27:1041-6.
21. Okuyama C, Ushijima Y, Kubota T, et al. Utility of follow-up studies using meta-[123 I]iodobenzylguanidine scintigraphy for detecting recurrent neuroblastoma. Nucl Med Commun 2002;23:663-72. (Pubitemid 34748006)
22. Simon T, Hero B, Hunneman DH, et al. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer 2003;39:1899-903. (Pubitemid 37311187)
23. Armstrong R, Sridhar M, Greenhalgh KL, et al. Phaeochromocytoma in children. Arch Dis Child 2008;93:899-904.
24. Wyszynska T, Cichocka E, Wieteska-Klimczak A, et al. A single pediatric center experience with 1025 children with hypertension. Acta Paediatr 1992;81:244-6.
25. Grinsell MM, Norwood VF. At the bottom of the differential diagnosis list: unusual causes of pediatric hypertension. Pediatr Nephrol 2009;24:2137-46.
26. McCrindle BW. Assessment and management of hypertension in children and adolescents. Nat Rev Cardiol 2010;7:155-63.
27. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002;287:1427-34.
28. Sullivan J, Groshong T, Tobias JD. Presenting signs and symptoms of pheochromocytoma in pediatric-aged patients. Clin Pediatr (Phila) 2005;44:715-19. (Pubitemid 41513010)
29. Sawka AM, Prebtani AP, Thabane L, et al. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma. BMC Endocr Disord 2004;4:2.
30. Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002;346:1041-6. (Pubitemid 34984617)
31. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med 2002;346:1047-53. (Pubitemid 34984618)
32. Stabell N, Nordal E, Stensvold E, et al. Febrile neutropenia in children with cancer: a retrospective Norwegian multicentre study of clinical and microbiological outcome. Scand J Infect Dis 2007;40:301-7.
33. Krug P, Schleiermacher G, Michon J, et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 2010;14:400-9.
34. Tate ED, Allison TJ, Pranzatelli MR, et al. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs 2005;22:8-19. (Pubitemid 40091116)